Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed
2011-001111-31Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-squamous non-small cell lung cancer comparing Trebananib + pemetrexed with Placebo + pemetrexed (2 arms). Primary endpoints: Incidence of adverse events and clinical laboratory abnormalities (Part 1) and Overall survival (OS). Started Jun 2013; status: completed.
02
Drugs
trebananib
03
Conditions
non-squamous non-small cell lung cancer
Beyond the preview
Go deeper on 2011-001111-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001111-31.